AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
Relapsed or Refractory Multiple Myeloma|Relapsed or Refractory Acute Myeloid Leukemia
DRUG: AMG 176|DRUG: Azacitidine|DRUG: Itraconazole
Multiple Myeloma (MM) Part 1a Incidence of dose-limiting toxicities (DLTs), Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the maximum tolerated dose (MTD) for two-consecutive days per week dosing schedule (QD2), Up to 6 months|MM Part 1a Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2, Up to 18 months|MM Part 1a Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2, Up to 18 months|MM Part 1a Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2, Up to 6 months|MM Part 1a Incidence of clinically significant changes in electrocardiograms (ECGs), Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2, Up to 6 months|MM Part 1a Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for QD2, Up to 6 months|MM Part 1a Pharmacokinetic (PK) parameters for AMG 176: maximum observed concentration (Cmax), Evaluate the pharmacokinetics (PK) of AMG 176 when administered as monotherapy QD2, 1 month on treatment|MM Part 1a Pharmacokinetic parameters for AMG 176: area under the concentration-time curve (AUC), Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|MM Part 1a Pharmacokinetic parameters for AMG 176: clearance (CL), Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|MM Part 1a Pharmacokinetic parameters for AMG 176: half-life (t1/2), Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|MM Part 1b Incidence of DLTs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a once weekly (QW) dosing schedule, Up to 6 months|MM Part 1b Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule, Up to 18 months|MM Part 1b Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule, Up to 18 months|MM Part 1b Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule, Up to 6 months|MM Part 1b Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule, Up to 6 months|MM Part 1b Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory MM and determine the MTD for a QW dosing schedule, Up to 6 months|MM Part 1b Pharmacokinetic parameters for AMG 176: Cmax, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|MM Part 1b Pharmacokinetic parameters for AMG 176: AUC, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|MM Part 1b Pharmacokinetic parameters for AMG 176: CL, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|MM Part 1b Pharmacokinetic parameters for AMG 176: t1/2, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|Acute Myeloid Leukemia (AML) Part 3a Incidence of DLTs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3a Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 18 months|AML Part 3a Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 18 months|AML Part 3a Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3a Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3a Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 monotherapy in subjects with relapsed or refractory AML and determine the MTD for QD2 dosing as a monotherapy in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3a Pharmacokinetic parameters for AMG 176: Cmax, Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|AML Part 3a Pharmacokinetic parameters for AMG 176: AUC, Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|AML Part 3a Pharmacokinetic parameters for AMG 176: CL, Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|AML Part 3a Pharmacokinetic parameters for AMG 176: t1/2, Evaluate the PK of AMG 176 when administered as monotherapy QD2, 1 month on treatment|AML Part 3b Incidence of DLTs, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3b Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 18 months|AML Part 3b Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 18 months|AML Part 3b Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3b Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3b Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 monotherapy (QW) in subjects with relapsed or refractory AML, Up to 6 months|AML Part 3b Pharmacokinetic parameters for AMG 176: Cmax, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|AML Part 3b Pharmacokinetic parameters for AMG 176: AUC, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|AML Part 3b Pharmacokinetic parameters for AMG 176: CL, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|AML Part 3b Pharmacokinetic parameters for AMG 176: t1/2, Evaluate the PK of AMG 176 when administered as monotherapy QW, 1 month on treatment|AML Part 3c Incidence of DLTs, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 6 months|AML Part 3c Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 18 months|AML Part 3c Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 18 months|AML Part 3c Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 6 months|AML Part 3c Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 6 months|AML Part 3c Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 QW monotherapy in participants in Japan with relapsed or refractory AML, Up to 6 months|AML Part 3c Pharmacokinetic parameters for AMG 176: Cmax, Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan, 1 month on treatment|AML Part 3c Pharmacokinetic parameters for AMG 176: AUC, Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan, 1 month on treatment|AML Part 3c Pharmacokinetic parameters for AMG 176: CL, Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan, 1 month on treatment|AML Part 3c Pharmacokinetic parameters for AMG 176: t1/2, Evaluate the PK of AMG 176 when administered as monotherapy (QW) in Japan, 1 month on treatment|AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: Cmax, Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: AUC, Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: CL, Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Pharmacokinetic parameters for AMG 176 and itraconazole: t1/2, Evaluate the PK of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 4 Incidence of DLTs, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the maximum tolerated combination dose (MTCD) of AMG 176 in combination with azacitidine, Up to 6 months|AML Part 4 Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine, Up to 18 months|AML Part 4 Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine, Up to 18 months|AML Part 4 Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine, Up to 6 months|AML Part 4 Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine, Up to 6 months|AML Part 4 Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML and determine the MTCD of AMG 176 in combination with azacitidine, Up to 6 months|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: Cmax, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: AUC, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: CL, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine: t1/2, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 5 Incidence of treatment-related adverse events, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML, Up to 18 months|AML Part 5 Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML, Up to 18 months|AML Part 5 Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML, Up to 6 months|AML Part 5 Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML, Up to 6 months|AML Part 5 Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 in combination with azacitidine in subjects with relapsed or refractory AML, Up to 6 months|AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: Cmax, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: AUC, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: CL, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment|AML Part 5 Pharmacokinetic parameters for AMG 176 and azacitidine: t1/2, Evaluate the PK of AMG 176 and azacitidine when administered in combination, 1 month on treatment
MM Part 1a Overall response (OR) according to International Myeloma Working Group uniform response criteria (IMWG-URC) for MM subjects, Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1a Progression-free survival (PFS), Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1a Time to response, Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1a Duration of response (DOR), Evaluate preliminary efficacy of AMG 176 QD2 when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1a BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts, Demonstrate inactivation of myeloid cell leukemia sequence 1 (MCL1) by the increase of active Bcl 2 associated X protein (BAX) and caspase 3 in circulating monocytes and/or the decrease of circulating monocytes in AMG 176 QD2 treated subjects, 6 months on treatment|MM Part 1b BAX and caspase 3 expression in circulating monocytes and/or circulating monocyte counts, Demonstrate inactivation of MCL1 by the increase of active BAX and caspase 3 in circulating monocytes and /or the decrease of circulating monocytes in AMG 176 QW treated subjects, 6 months on treatment|MM Part 1b Overall response (OR) according to IMWG-URC for MM subjects, Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1b Progression free survival (PFS), Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1b Time to response, Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM, 6 months on treatment|MM Part 1b Duration of response (DOR), Evaluate preliminary efficacy of AMG 176 QW when given as monotherapy in relapsed or refractory MM, 6 months on treatment|AML Part 3a, 3b and 3c Overall response (OR) according to the 2017 European Leukemia Net (ELN) criteria (DÃ¶hner et al, 2017), Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML, 6 months on treatment|AML Part 3a, 3b and 3c Event free survival (EFS), Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML, 6 months on treatment|AML Part 3a, 3b and 3c Time to response, Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML, 6 months on treatment|AML Part 3a, 3b and 3c Duration of response (DOR), Evaluate preliminary efficacy of AMG 176 when given as monotherapy in relapsed or refractory AML, 6 months on treatment|AML Part 3d Incidence of treatment-emergent adverse events, Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Incidence of clinically significant changes in vital signs, Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Incidence of clinically significant changes in ECGs, Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 3d Incidence of clinically significant changes in clinical laboratory tests, Evaluate the safety and tolerability of AMG 176 when given alone and in combination with itraconazole in subjects with AML, 3 weeks on treatment|AML Part 4 Overall response (OR) according to the 2017 ELN criteria in AML subjects, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 4 Event free survival (EFS), Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 4 Time to response, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 4 Duration of response (DOR), Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 5 OR according to the 2017 ELN criteria in AML subjects, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 5 EFS, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 5 Time to response, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment|AML Part 5 DOR, Evaluate preliminary efficacy of AMG 176 when given in combination with azacitidine in relapsed or refractory AML, 6 months on treatment
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia The study will be conducted in five parts.